IMMUNITYBIO, INC. (IBRX) Net margin 2016–2025
IMMUNITYBIO, INC. (IBRX) net profit margin by fiscal year — reported net income divided by reported revenue.
-310.2%FY2025 · since FY2016: -274565.9% → -310.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -310.2% | +2494.6 pp |
| FY2024 | -2804.8% | +90956.6 pp |
| FY2023 | -93761.4% | +79808.2 pp |
| FY2022 | -173569.6% | -136440.0 pp |
| FY2021 | -37129.6% | -460.0 pp |
| FY2020 | -36669.6% | -29504.4 pp |
| FY2019 | -7165.2% | +197571.0 pp |
| FY2018 | -204736.2% | +9537.2 pp |
| FY2017 | -214273.3% | +60292.6 pp |
| FY2016 | -274565.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating marginIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →